Menu
 
Research menu
Jump to menu

Publications:  Dr Patricia McGettigan

Rashid F, Suresan S, McGettigan P (2020). Prescribing a single inhaler type: Audit of inhaler prescribing in two London general practices. BRITISH JOURNAL OF PHARMACOLOGY. vol. 177, 2600-2600.
Schjerning A-M, McGettigan P, Gislason GH(2020). Reply to 'Aspirin as a painkiller in patients with a high cardiovascular risk profile'. Nat Rev Cardiol
10.1038/s41569-020-0399-3
Schjerning A-M, McGettigan P, Gislason G(2020). Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol
10.1038/s41569-020-0366-z
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65295
Ferner R, McGettigan P(2020). The patient who reports a drug allergy. BMJ vol. 368,
10.1136/bmj.l6791
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63661
McGettigan P, Olmo CA, Plueschke K, Castillon M, Zondag D, Bahri P, Kurz X, Mol PGM(2019). Authors' Reply to Ravi Jandhyala's Comment on "Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments". Drug Saf vol. 42, (12) 1517-1518.
10.1007/s40264-019-00863-w
Schjerning Olsen A-M, Mcgettigan P, Gerds TA, Fosbøl EL, Olesen JB, Sindet-Pedersen C, Staerk L, Hansen ML et al.(2019). Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. European Heart Journal - Cardiovascular Pharmacotherapy
10.1093/ehjcvp/pvz069
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62539
McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, Kurz X, Mol PGM(2019). Correction to: Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf vol. 42, (11)
10.1007/s40264-019-00859-6
McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, Kurz X, Mol PGM(2019). Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf vol. 42, (11) 1343-1351.
10.1007/s40264-019-00848-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/61516
Schuster Bruce C, Brhlikova P, Heath J, McGettigan P(2019). The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. PLoS Med vol. 16, (9)
10.1371/journal.pmed.1002873
https://qmro.qmul.ac.uk/xmlui/handle/123456789/60087
Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X(2019). Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy. JAMA Neurol vol. 76, (7) 827-833.
10.1001/jamaneurol.2019.0887
https://qmro.qmul.ac.uk/xmlui/handle/123456789/60811
McGettigan P, Olmo CA, Plueschke K, Castillon M, Zondag D, Bahri P, Kurz X, Mol P (2019). Improving the use of patient registries in regulatory evaluations. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. vol. 85, 1652-1652.
Barcella CA, Lamberts M, McGettigan P, Fosbøl EL, Lindhardsen J, Torp-Pedersen C, Gislason GH, Olsen A-MS(2019). Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy-A nationwide study in patients with osteoarthritis. Basic Clin Pharmacol Toxicol vol. 124, (5) 629-641.
10.1111/bcpt.13182
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56088
Olmo CA, McGettigan P, Kurz X(2019). Barriers and Opportunities for Use of Patient Registries in Medicines Regulation. Clinical Pharmacology and Therapeutics vol. 106, (1) 39-42.
10.1002/cpt.1414
https://qmro.qmul.ac.uk/xmlui/handle/123456789/60816
Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X(2019). Correction to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study. Clin Drug Investig vol. 39, (2)
10.1007/s40261-019-00755-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58918
Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X(2019). Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study. Clin Drug Investig vol. 39, (2) 205-213.
10.1007/s40261-018-0729-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62044
Ferner R, McGettigan P(2018). Adverse drug reactions (vol 363, K4051, 2018). BMJ-BRITISH MEDICAL JOURNAL vol. 363, Article ARTN k4777,
10.1136/bmj.k4777
Ferner RE, McGettigan P(2018). Adverse drug reactions. BMJ vol. 363,
10.1136/bmj.k4051
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53568
Pacurariu A, Plueschke K, McGettigan P(2018). Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation (vol 8, e023090, 2018). BMJ OPEN vol. 8, (11)
10.1136/bmjopen-2018-023090corr1
Pacurariu A, Plueschke K, McGettigan P, Morales DR, Slattery J, Vogl D, Goedecke T, Kurz X et al.(2018). Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open vol. 8, (9)
10.1136/bmjopen-2018-023090
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53743
Morales DR, Slattery J, Pacurariu A, McGettigan P, Kurz X (2018). Association between systemic fluoroquinolone exposure and tendon rupture: Population-based nested case-control study. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. vol. 27, 339-339.
Plueschke K, McGettigan P, Pacurariu A, Kurz X, Cave A(2018). EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making. BMJ Open vol. 8, (6)
10.1136/bmjopen-2018-021864
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53569
McGettigan P, Roderick P, Kadam A, Pollock A(2018). Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. British Journal of Clinical Pharmacology vol. 85, (1) 59-70.
10.1111/bcp.13503
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62099
MCGETTIGAN P, Roderick P, Kadam A, Pollock A(2017). Access, Watch, and Reserve antibiotics in India: challenges for WHO stewardship. The Lancet Global Health vol. 5, (11) e1075-e1076.
10.1016/S2214-109X(17)30365-0
https://qmro.qmul.ac.uk/xmlui/handle/123456789/28224
Plueschke K, Kurz X, Cave A, McGettigan P, Pacurariu A (2017). Supporting Pharmacovigilance by Landscaping EU-funded Real World Data. DRUG SAFETY. vol. 40, 949-949.
McGettigan P, Olsen A-MS(2017). NSAIDs for high-risk patients: none, celecoxib, or naproxen?. Lancet vol. 389, (10087) 2351-2352.
10.1016/S0140-6736(17)30980-7
McGettigan P, Ferner RE(2017). PCSK9 inhibitors for hypercholesterolaemia. BMJ vol. 356,
10.1136/bmj.j188
McGettigan P, McKendree J(2016). Presence of Medical Students and Length of Stay in the Emergency Department. JAMA vol. 315, (18)
10.1001/jama.2016.1577
Matin N, Trivedi B, Holyoak H, McGettigan P (2016). Combined HIV/cardiovascular clinic: review of patient cohort and analysis of outcomes. HIV MEDICINE. vol. 17, 47-47.
McGettigan P, McKendree J(2015). Interprofessional training for final year healthcare students: a mixed methods evaluation of the impact on ward staff and students of a two-week placement and of factors affecting sustainability. BMC Med Educ vol. 15,
10.1186/s12909-015-0436-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12248
Schjerning Olsen A-M, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosbøl E, Køber L, Torp-Pedersen C et al.(2015). Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ vol. 351,
10.1136/bmj.h5096
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12199
Olsen AMS, Lindhardsen J, Gislason G, McGettigan P, Hlatky M, Koeber L, Torp-Pedersen C, Lamberts M (2015). Impact of PPI treatment on gastrointestinal bleeding associated with NSAID use among post-myocardial infarction patients on antithrombotic therapy - A nationwide study. EUROPEAN HEART JOURNAL. vol. 36, 1152-1152.
McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock AM(2015). Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs. PLoS Med vol. 12, (5)
10.1371/journal.pmed.1001826
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12349
Schjerning Olsen A-M, Gislason GH, McGettigan P, Fosbøl E, Sørensen R, Hansen ML, Køber L, Torp-Pedersen C et al.(2015). Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA vol. 313, (8) 805-814.
10.1001/jama.2015.0809
McGettigan P, Pollock A, Herxheimer A(2014). Department of Health's misguided alert recommending neuraminidase inhibitors for flu. BMJ vol. 348,
10.1136/bmj.g1594
McGettigan P, Pollock A, Herxheimer A(2014). OSELTAMIVIR AND ZANAMIVIR FOR FLU Department of Health's misguided alert recommending neuraminidase inhibitors for flu. BMJ-BRITISH MEDICAL JOURNAL vol. 348, Article ARTN g1594,
10.1136/bmj.g1594
Roderick P, Mahajan R, McGettigan P, Pollock AM(2014). India should introduce a new Drugs Act. Lancet vol. 383, (9913) 203-206.
10.1016/s0140-6736(14)60059-3
Herxheimer A, McGettigan P(2013). Problems of polypharmacy. BMJ vol. 347,
10.1136/bmj.f7500
McGettigan P, Henry D(2013). Use of NSAIDs with Increased Risk of Cardiovascular Events in Low and Middle Income Countries. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY vol. 22, 423-423.
McGettigan P, McKendree J, Reed N, Holborow S, Walsh CD, Mace T(2013). Identifying attributes required by Foundation Year 1 doctors in multidisciplinary teams: a tool for performance evaluation. BMJ Qual Saf vol. 22, (3) 225-232.
10.1136/bmjqs-2012-001418
McGettigan P, Henry D(2013). Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med vol. 10, (2)
10.1371/journal.pmed.1001388
https://qmro.qmul.ac.uk/xmlui/handle/123456789/5139
McGettigan P, Lincz LF, Attia J, McElduff P, Bissett L, Peel R, Stokes B, Hancock S et al.(2011). The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene. BRIT J CLIN PHARMACO vol. 72, (4) 707-714.
10.1111/j.1365-2125.2011.03957.x
McGettigan P, Henry D(2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med vol. 8, (9)
10.1371/journal.pmed.1001098
https://qmro.qmul.ac.uk/xmlui/handle/123456789/5414
McGettigan P, Henry D(2011). Cardiovascular Events after Prescription of NSAIDs - Updated Systematic Review of Pharmaco-Epidemiological Studies. PHARMACOEPIDEM DR S vol. 20, S324-S325.
Waring WS, McGettigan P(2011). Clinical toxicology and drug regulation: A United Kingdom perspective. CLIN TOXICOL vol. 49, (6) 452-456.
10.3109/15563650.2011.594054
McGettigan P, Henry D(2011). EVALUATION OF CARDIOVASCULAR RISK WITH NSAIDS: LIMITATIONS ARISING FROM INCONSISTENT REPORTING IN PHARMACOEPIDEMIOLOGICAL STUDIE. BASIC CLIN PHARMACOL vol. 109, 139-139.
McGettigan P, Henry D(2011). PHARMACOEPIDEMIOLOGICAL STUDIES ADVANCE THE INFORMATION FROM RANDOMIZED TRIALS INVESTIGATING NSAID ASSOCIATED CARDIOVASCULAR RISK. BASIC CLIN PHARMACOL vol. 109, 25-25.
Henry D, Lincz L, Attia J, McElduff P, Bisset L, Peel R, Hancock S, Henderson K et al.(2009). POLYMORPHISMS IN TWO REGIONS OF THE CYCLO-OXYGENASE-2 GENE ASSOCIATED WITH VARIATION IN RISK OF CORONARY THROMBOSIS WITH CYCLO-OXYGENASE-2 INHIBITORS. BASIC CLIN PHARMACOL vol. 105, 39-39.
Henry D, Lincz L, Attia J, McElduff P, Bisset L, Peel R, Hancock S, Henderson K et al.(2009). Polymorphisms in Two Regions of the Cyclo-Oxygenase-2 Gene Associated with Variation in Risk of Coronary Thrombosis with Cyclo-Oxygenase-2 Inhibitors. PHARMACOEPIDEM DR S vol. 18, S116-S116.
McGettigan P, Dakkak E, Morris I(2009). TRAINING MEDICAL STUDENTS TO PRESCRIBE: HYMS' EVOLVING TEACHING MODEL. BASIC CLIN PHARMACOL vol. 105, 42-42.
McGettigan P, Peel R, Stokes B, Henderson K, Whitaker D, Henry D(2009). WHAT DID 'SAFE' MEAN TO PRESCRIBERS OF SELECTIVE COX-2 INHIBITORS?. BASIC CLIN PHARMACOL vol. 105, 90-90.
Ringland C, Mant A, McGettigan P, Mitchell P, Kelman C, Buckley N, Pearson SA(2008). Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. BRIT J CLIN PHARMACO vol. 66, (5) 682-688.
10.1111/j.1365-2125.2008.03253.x
McGettigan P, Han P, Jones L, Whitaker D, Henry D(2008). Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. BRIT J CLIN PHARMACO vol. 65, (6) 927-934.
10.1111/j.1365-2125.2008.03121.x
Moxey AJ, Adams CA, Stokes B, McGettigan P(2007). Describing treatment options to patients with cancer: The influence of information framing. PSYCHO-ONCOL vol. 16, (9) S168-S169.
Attia J, Thakkinstian A, Wang Y, Lincz L, Parsons M, Sturm J, McGettigan P, Scott R et al.(2007). The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. J Stroke Cerebrovasc Dis vol. 16, (4) 173-179.
10.1016/j.jstrokecerebrovasdis.2007.03.002
Henry D, McGettigan P(2007). Cyclooxygenase inhibitors and cardiovascular risk - Reply. JAMA-J AM MED ASSOC vol. 297, (6) 587-588.
10.1001/jama.297.6.587
Henry D, McGettigan P(2007). Selective COX-2 inhibitors: A promise unfulfilled?. GASTROENTEROLOGY vol. 132, (2) 790-794.
10.1053/j.gastro.2007.01.017
McGettigan P, Henry D(2006). Cardiovascular risk and inhibition of cyclooxygenase - A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA-J AM MED ASSOC vol. 296, (13) 1633-1644.
10.1001/jama.296.13.jrv60011
Moxey AJ, Adams CA, McGettigan P(2006). Making treatment decisions for cancer: What do patients consider?. PSYCHO-ONCOL vol. 15, (2) S338-S339.
McGettigan P, Han P, Henry D(2006). Cyclooxygenase-2 inhibitors and coronary occlusion - exploring dose-response relationships. BRIT J CLIN PHARMACO vol. 62, (3) 358-365.
10.1111/j.1365-2125.2006.02660.x
Robertson J, McGettigan P(2006). What price research?. Aust Fam Physician vol. 35, (1-2)
Robertson J, Walkom EJ, McGettigan P(2005). Response rates and representativeness: a lottery incentive improves physician survey return rates. PHARMACOEPIDEM DR S vol. 14, (8) 571-577.
10.1002/pds.1126
McGettigan P, Henry D(2005). Medical research and the news media. NEW ENGL J MED vol. 352, (8) 838-838.
10.1056/nejm200502243520821
Moxey A, O'Connell D, McGettigan P, Henry D (2003). Describing treatment effects to patients - How they are expressed makes a difference. JOURNAL OF GENERAL INTERNAL MEDICINE. vol. 18, 948-U8.
10.1046/j.1525-1497.2003.20928.x
Moxey A, O'Connell D, McGettigan P, Henry D(2003). Describing treatment effects to patients. J Gen Intern Med vol. 18, (11) 948-959.
10.1046/j.1525-1497.2003.20928.x
Henry D, McGettigan P (2003). Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 43-49.
Isbister GK, Whyte IM, Downes F, Dawson AH, McGettigan P(2003). Concomitant overdosing of other drugs in patients with paracetamol poisoning. BRIT J CLIN PHARMACO vol. 55, (3) 325-325.
10.1046/j.1365-2125.2003.01761.x
Henry D, McGettigan P(2003). Upper gastrointestinal event risk with COX-2 inhibitors depended on known risk factors. ACP J Club vol. 138, (2)
Isbister GK, McGettigan P, Harris I(2003). Hyperbaric oxygen for acute carbon monoxide poisoning. NEW ENGL J MED vol. 348, (6) 558-558.
Isbister GK, McGettigan P, Harris I(2003). Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med vol. 348, (6) 557-560.
10.1056/nejm200302063480615
McGettigan P, Isbister GK, Whyte IM(2003). Adolescent depression. NEW ENGL J MED vol. 348, (5) 473-473.
10.1056/NEJM200301303480521
Isbister GK, McGettigan P, Dawson A(2001). A fatal case of moclobemide-citalopram intoxication. J ANAL TOXICOL vol. 25, (8) 716-717.
10.1093/jat/25.8.716
McGettigan P, Golden J, Fryer J, Chan R, Feely J(2001). Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message. BRIT J CLIN PHARMACO vol. 51, (2) 184-189.
10.1111/j.1365-2125.2001.01332.x
Smith AJ, McGettigan P(2000). Quality use of medicines in the community: the Australian experience. BRIT J CLIN PHARMACO vol. 50, (6) 515-519.
10.1046/j.1365-2125.2000.00291.x
McGettigan P, Kelly A, Carvahlo M, Feely J(2000). Anti-depressants in primary care: Analysis of treatment discontinuations. PHARMACOEPIDEM DR S vol. 9, (6) 521-528.
10.1002/1099-1557(200011)9:6<521::AID-PDS525>3.0.CO;2-K
McGettigan P, Henry D(2000). Current problems with non-specific COX inhibitors. CURR PHARM DESIGN vol. 6, (17) 1693-1724.
10.2174/1381612003398690
McGettigan P(2000). COX-2 inhibitors. What is their place?. Aust Fam Physician vol. 29, (9) 847-852.
Feely T, McGettigan P, Kelly A(2000). Growth in use of statins after trials is not targeted to most appropriate patients. CLIN PHARMACOL THER vol. 67, (4) 438-441.
10.1067/mcp.2000.105152
McGettigan P, Sly K, O'Connell D, Hill S, Henry D(1999). The effects of information framing on the practices of physicians. J GEN INTERN MED vol. 14, (10) 633-642.
10.1046/j.1525-1497.1999.09038.x
Henry D, McGettigan P(1999). Cardiac and renal failure due to NSAIDs: a review of the epidemiological literature. Inflammopharmacology vol. 7, (3) 311-338.
10.1007/s10787-999-0015-y
McGettigan P, Henry D, Page J (1998). Adverse effects of non-steroidal anti-inflammatory drugs on the gastrointestinal tract and kidney: relationship to cyclooxygenase-2 selectivity. CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS. Editors: Vane, JR, Botting, RM, 149-160.
Belton KJ, Gram LF, Royer RJ, Feely J, McGettigan P, Velo GP, Conforti A, Leone R et al.(1997). Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. EUR J CLIN PHARMACOL vol. 52, (6) 423-427.
10.1007/s002280050314
McGettigan P, Mooney EE, Sinnott M, Sweeney EC, Feely J(1997). Sudden death in Whipple's disease. POSTGRAD MED J vol. 73, (862) 509-511.
10.1136/pgmj.73.862.509
McGettigan P, Golden J, Conroy RM, Arthur N, Feely J(1997). Reporting of adverse drug reactions by hospital doctors and the response to intervention. BRIT J CLIN PHARMACO vol. 44, (1) 98-100.
10.1046/j.1365-2125.1997.00616.x
McGettigan P, McManus J, OShea B, Chan R, Feely J(1997). Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: Prescribers' concerns. IRISH MED J vol. 90, (4) 146-147.
Hemeryck L, McGettigan P, Feely J(1997). Hospital antibiotic prescribing and feedback. BRIT J CLIN PHARMACO vol. 43, (4) 449-450.
Feely J, Golden J, Chan R, McGettigan P(1997). Who is kidding who? Sources of influence when prescribing new drugs. CLIN PHARMACOL THER vol. 61, (2) PII80-PII80.
Wen Y, Killalea S, McGettigan P, Feely J(1996). Lipid peroxidation and antioxidant vitamins C and E in hypertensive patients. IRISH J MED SCI vol. 165, (3) 210-212.
10.1007/BF02940252
LEE TC, ODRISCOLL KJ, MCGETTIGAN P, MORAES D, RAMPHALL S, OBRIEN M(1988). THE SITE OF THE TENDINOUS INTERRUPTION IN SEMITENDINOSUS IN MAN. J ANAT vol. 157, 229-231.
Return to top